达格列净联合沙库巴曲缬沙坦钠治疗急性心肌梗死经皮冠状动脉介入治疗术后心力衰竭患者的疗效OA

Objective To explore the efficacy of dagliflozin combined with sarcovalsartan sodium(ARNI)on heart failure after acute myocardial infarction(AMI)patients with heart failure after percutaneous coronary intervention(PCI)and its effect on serum hypersensitive C-reactive protein(hs-CRP)and n-terminal brain natriuretic peptide precursor(NT-proBNP).Methods Sixty AMI patients with heart failure after PCI treated in Jinqiu Hospital of Liaoning Province from January 2022 to January 2024 were selected as the study objects,and were divided into control group and observation group according to different treatment methods,with 30 cases in each group.The control group was treated with dagaglizin tablets,and the observation group was treated with ARNI on the basis of the control group.The therapeutic effect of the two groups was compared.Results After treatment,left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)in observation group were lower than those in control group,and left ventricular ejection fraction(LVEF)was higher than that in control group,the difference was statistically significant(P＜0.05).After treatment,serum procalcitonin(PCT),tumor necrosis factor α(TNF-α),interleukin-6(IL-6),hs-CRP and NT-proBNP in observation group were lower than those in control group(P＜0.05).The incidence of major cardiovascular adverse events in observation group was lower than that in control group(P＜0.05).Conclusion Daglizin combined with ARNI is effective in the treatment of heart failure in AMI patients after PCI,which can effectively improve the heart function of patients,reduce inflammation,and reduce the occurrence of cardiovascular adverse events.